mRNA Leading Expert Kenneth Chien and Novalis LifeSciences’ Marijn Dekkers Investing EUR 39M Series B2 Financing in mRNA Technology Platform Company eTheRNA
August 23, 2022 08:00 ET
|
eTheRNA Immunotherapies NV
Financing round led by Novalis LifeSciences LLCBoth investors Dr. Marijn Dekkers and Moderna’s co-founder Dr. Kenneth Chien to join the board of directorsStrategic focus includes customized lipid...
eTheRNA Announces Relocation and Expansion of R&D Facility
April 05, 2022 07:00 ET
|
eTheRNA Immunotherapies NV
GENT, Belgium, April 05, 2022 (GLOBE NEWSWIRE) -- eTheRNA immunotherapies NV (“eTheRNA”), an mRNA technology discovery and development company with a full platform of integrated capabilities, is...
eTheRNA Manufacturing Announces New LNP Formulation Development and Production Service
March 28, 2022 07:00 ET
|
eTheRNA Immunotherapies NV
NIEL, Belgium, March 28, 2022 (GLOBE NEWSWIRE) -- eTheRNA Manufacturing, a specialist RNA process developer and manufacturing member of the Belgian eTheRNA group, is introducing a new Lipid...
eTheRNA Immunotherapies to Host Key Opinion Leader Webinar on mRNA-Lipid Nanoparticles for Cancer Immunotherapy
February 28, 2022 07:00 ET
|
eTheRNA Immunotherapies NV
NIEL, Belgium, Feb. 28, 2022 (GLOBE NEWSWIRE) -- eTheRNA immunotherapies NV (‘eTheRNA’), an mRNA technology discovery and development company with a full platform of integrated capabilities, today...